TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an update.
Perseus Proteomics Inc. announced the completion of a clinical study report for its Phase I trial of PPMX-T003, an anti-transferrin receptor 1 antibody, in patients with polycythemia vera. The trial, which involved six subjects, demonstrated safety and indicated efficacy, with five subjects experiencing a 12-week period without the need for phlebotomy. The results have no impact on the company’s fiscal year 2025/3 business results.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is engaged in the research and development of innovative treatments, with a particular emphasis on addressing unmet medical needs.
YTD Price Performance: 28.29%
Average Trading Volume: 639,280
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen10.17B
See more data about 4882 stock on TipRanks’ Stock Analysis page.